COVID-19 Testing

Do You Run a Business?  Now Get Streamlined COVID-19 Antibody Testing for Your Entire Staff!

Apollo Med Innovations in Joint Venture with Olympus Health has created a nationwide mobile COVID-19 antibody testing offering.   Mobile testing at employer locations or centralized facilities provides unprecedented convenience and peace of mind for Essential Businesses and Critical Infrastructure employees, so that these critical employees and employers can continue to provide essential products and services by demonstrating adaptive immune response to this virus.  The Apollo Med/Olympus Health joint venture utilizes an FDA-validated antibody test that has been reviewed under the FDA’s Emergency Use Authorization designation and requires a simple blood sample and results are generally available in under 15 minutes.

Testing is covered by most company-sponsored insurance providers making the cost to the corporation limited to a low mobile delivery fee.

Businesses can benefit from knowing which employees are the least susceptible to new coronavirus infections.  If employee safety is your top priority and you wish to identify which employees are the least likely to catch and spread the coronavirus, call us at (844) 698-4782 to discuss setting up employee testing for your business or contact us via the form below.

About The Test

COVID-19 IgG/IgM Rapid Test uses whole blood, serum or plasma for rapid, qualitative, and differential detection of IgG and IgM antibodies in 15 minutes or less. The test is FDA-validated via the FDA’s Emergency Use Authorization (EUA) policy and is CE marked, which means it’s manufactured to European Economic Area standards for health, safety, and environmental protection.  All antibody tests are performed by medical professionals onsite at your location.

GENERAL DISCLAIMER: The test is being made available under compliance with Section IV.D. of the FDA’s Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency. Updated FDA guidance, issued on March 16, 2020, allows the distribution of this product for diagnostic use in laboratories or by healthcare workers at the point-of-care. View the updated policy.